This segment focuses on the research, development, and commercialization of injectable collagenase clostridium histolyticum (CCH) for various medical conditions. The primary technology involves the use of CCH, a purified enzyme derived from bacteria, to break down collagen and treat conditions characterized by excessive collagen deposition. Research and development activities include clinical trials for new indications, formulation improvements, and exploring novel delivery methods. The therapeutic areas covered include Dupuytren's contracture, Peyronie's disease (under the brand names XIAFLEX and Xiapex), and potential treatments for frozen shoulder, cellulite, and uterine fibroids. The patient impact is significant, offering minimally invasive treatment options and improved outcomes for patients suffering from these debilitating conditions. Market positioning is strong, with XIAFLEX being a leading treatment for Dupuytren's contracture. Future opportunities lie in expanding the label for existing products and developing new CCH-based therapies. Regulatory and clinical aspects involve obtaining FDA approval for new indications and conducting post-market surveillance. Partnerships with pharmaceutical companies like Endo Global Ventures are crucial for commercialization and market access.